This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19...
The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different che...
Treatment protocols for classical Hodgkin lymphoma (HL) are provided below, including treatment for early-stage, advanced-stage, and relapsed/refractory disease. General guidelines follow. Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on ...
TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment...
Radiation therapy (or radiotherapy) for Hodgkin lymphoma uses high-energy rays to destroy lymphoma cells when a tumor has formed. It’s typically given in combination with chemotherapy. Together, these two treatments tend to be successful in shrinking a tumor that’s found, typically in the chest...
Introduction Classic Hodgkin lymphoma (cHL) is a cancer of the immune system. Combination chemotherapy and radiation therapy result in high cure rate, nevertheless, up to a quarter of patients with advanced stage cHL may relapse. One mechanism of relapse is through immune evasion; cHL can avoid ...
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma Article03 March 2021 Introduction Despite considerable advances in the allogeneic hematopoietic stem cell transplantation (allo-HSCT)1, relapse remains the major cause of transplant failure in patients with acute lymphoblastic leukemia...
Purpose: Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different milestones during th... JL Biccler,I Glimelius,S Eloranta,... - 《Journal of...
Anti-TNF drugs may increase lymphoma risk in autoimmune rheumatic diseases, such as rheumatoid arthritis, but there have been no reports stating increased risk of lymphoma in ankylosing spondylitis (AS). Before 2years, we had presented a case with AS developing Hodgkin's lymphoma following 6months...
of non-Hodgkin lymphoma with a specific focus on data that highlight how these agents may be incorporated into current standard treatment approaches.doi... CB Reeder,SM Ansell - 《Blood》 被引量: 289发表: 2011年 Present status and perspectives regarding the therapeutic strategy for acute myeloid...